Malwa Drugs Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 30 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
About Malwa Drugs
Malwa Drugs Pvt Ltd (MDPL) is a Private Limited Indian Non-Government Company incorporated in India on 07 March 1994 and has a history of 30 years and ten months. Its registered office is in Ratlam, Madhya Pradesh, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Sanjay Vyas, Sandeep Vyas, Rajesh Vyas, and Two other members serve as directors at the Company.
Company Details
-
Location
Ratlam, Madhya Pradesh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24232MP1994PTC008167
-
Company No.
008167
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
07 Mar 1994
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Gwalior
Industry
Who are the key members and board of directors at Malwa Drugs?
Board Members (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajesh Vyas
|
Director | 25-Sep-2000 | Current |
|
Sanjay Vyas
|
Director | 17-Mar-1994 | Current |
|
Sandeep Vyas
|
Director | 20-Dec-2016 | Current |
|
Neetu Vyas
|
Director | 25-Feb-2006 | Current |
|
Renu Vyas
|
Director | 25-Feb-2006 | Current |
Financial Performance of Malwa Drugs.
Malwa Drugs Pvt Ltd, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Malwa Drugs?
In 2017, Malwa Drugs had a promoter holding of 99.00% and a public holding of 1.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Skb Agrotech Private LimitedSanjay Vyas is a mutual person
-
Shailchem Distillate Private LimitedSanjay Vyas is a mutual person
-
Malwa Oxygen & Industrial Gases Private Limited
Sanjay Vyas is a mutual person
-
Mykan Chem Private Limited
Sanjay Vyas is a mutual person
-
Malwa Specialities Private Limited
Sanjay Vyas is a mutual person
-
Maa Kukki Charitable Foundation
Sanjay Vyas is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Malwa Drugs?
Unlock and access historical data on people associated with Malwa Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Malwa Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Malwa Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.